VBI Vaccines Reports New Tumor Response Data From Ongoing Randomized Controlled Phase 2b Study Of VBI-1901 For Patients With Recurrent Glioblastoma
Portfolio Pulse from Benzinga Newsdesk
VBI Vaccines has reported new tumor response data from its ongoing Phase 2b study of VBI-1901 for recurrent glioblastoma. Among 7 patients, one showed a partial tumor response and two had stable disease. The disease control rate in the VBI-1901 arm was 43%, compared to 0% in the control arm. The FDA has granted Fast Track and Orphan Drug Designations to VBI-1901. Additional interim data is expected in Q4 2024.
May 29, 2024 | 12:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
VBI Vaccines reported promising Phase 2b data for VBI-1901 in recurrent glioblastoma, showing a 43% disease control rate. The FDA has granted Fast Track and Orphan Drug Designations. Additional data is expected in Q4 2024.
The positive interim data from the Phase 2b study, along with the FDA's Fast Track and Orphan Drug Designations, are likely to boost investor confidence and positively impact VBIV's stock price in the short term. The anticipation of additional data in Q4 2024 adds further potential for upward movement.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100